U.S. markets open in 7 hours 24 minutes
  • S&P Futures

    4,276.25
    -10.25 (-0.24%)
     
  • Dow Futures

    33,931.00
    -50.00 (-0.15%)
     
  • Nasdaq Futures

    13,484.75
    -38.50 (-0.28%)
     
  • Russell 2000 Futures

    1,993.90
    -7.80 (-0.39%)
     
  • Crude Oil

    90.03
    -0.47 (-0.52%)
     
  • Gold

    1,769.00
    -2.20 (-0.12%)
     
  • Silver

    19.26
    -0.20 (-1.02%)
     
  • EUR/USD

    1.0080
    -0.0012 (-0.12%)
     
  • 10-Yr Bond

    2.8800
    0.0000 (0.00%)
     
  • Vix

    19.56
    -0.34 (-1.71%)
     
  • GBP/USD

    1.1911
    -0.0021 (-0.18%)
     
  • USD/JPY

    136.3360
    +0.4740 (+0.35%)
     
  • BTC-USD

    22,810.88
    -620.57 (-2.65%)
     
  • CMC Crypto 200

    542.33
    -15.40 (-2.76%)
     
  • FTSE 100

    7,541.85
    +26.10 (+0.35%)
     
  • Nikkei 225

    28,919.64
    -22.50 (-0.08%)
     

Novo Nordisk To Buy Prothena's ATTR Amyloidosis Program For Up To $1.2B

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Novo Nordisk A/S (NYSE: NVO) will acquire Prothena Corporation plc's (NASDAQ: PRTA) and clinical stage antibody PRX004 and broader ATTR amyloidosis program.

  • PRX004 is a Phase 2 ready immunotherapy designed to deplete the amyloid deposits associated with the disease pathology of ATTR amyloidosis.

  • ATTR amyloidosis is characterized by the abnormal buildup of amyloid deposits composed of misfolded transthyretin protein.

  • Prothena has completed a phase 1 study with PRX004 in patients with hereditary forms of ATTR, in which PRX004 was found to be safe and well-tolerated.

  • Novo Nordisk will initially focus on the clinical development of PRX004 in ATTR cardiomyopathy, characterized by the buildup of amyloid deposits in cardiac tissue.

  • Under the terms of the agreement, Prothena is eligible to receive milestone payments of up to $1.2 billion, including $100 million in upfront and near-term clinical milestone payments.

  • Price Action: PRTA stock is up 7.19% at $63.50, and NVO shares are up 0.2% at $86.71 during the premarket session on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.